Electrocardiographic assessment for therapeutic proteins—scientific discussion - 05/08/11
, Andrew Erdman, MD b, Desmond Padhi, PharmD c, Christine E. Garnett, PharmD d, Hong Zhao, PhD d, Shari L. Targum, MD d, Suchitra Balakrishnan, MD, PhD d, Colette Strnadova, PhD e, Norman Viner, MD e, Mary Jane Geiger, MD, PhD f, Christopher Newton-Cheh, MD, MPH g, h, Jeffrey Litwin, MD i, Michael K. Pugsley, PhD j, Philip T. Sager, MD k, Mitchell W. Krucoff, MD l, John K. Finkle, MD mRiassunto |
Electrocardiographic monitoring is an integral component of the clinical assessment of cardiac safety of all compounds in development. The International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use E14 guideline recommends a dedicated study to evaluate drug-induced effects on cardiac repolarization (“thorough QT/QTc study”). There has been limited published information on QT interval changes secondary to therapeutic proteins; however, in theory, biologic therapies may affect cardiac electrical activity either directly or indirectly. This article summarizes scientific discussions of members of the Cardiac Safety Research Consortium and includes possible approaches to consider for the clinical evaluation of drug-induced QT prolongation in development programs of therapeutic proteins.
Il testo completo di questo articolo è disponibile in PDF.Mappa
Vol 160 - N° 4
P. 627-634 - ottobre 2010 Ritorno al numero
Articolo precedente
- Developing the Safety of Atrial Fibrillation Ablation Registry Initiative (SAFARI) as a collaborative pan-stakeholder critical path registry model: A Cardiac Safety Research Consortium “Incubator” Think Tank
- Sana M. Al-Khatib, Hugh Calkins, Benjamin C. Eloff, Peter Kowey, Stephen C. Hammill, Kenneth A. Ellenbogen, Danica Marinac-Dabic, Albert L. Waldo, Ralph G. Brindis, David J. Wilbur, Warren M. Jackman, Marcia S. Yaross, Andrea M. Russo, Eric Prystowsky, Paul D. Varosy, Thomas Gross, Ellen Pinnow, Mintu P. Turakhia, Mitchell W. Krucoff
- Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: Design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation–Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF–TIMI 48)
- Christian T. Ruff, Robert P. Giugliano, Elliott M. Antman, Sharon E. Crugnale, Tomas Bocanegra, Michele Mercuri, James Hanyok, Indravadan Patel, Minggao Shi, Dan Salazar, Carolyn H. McCabe, Eugene Braunwald
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
Già abbonato a @@106933@@ rivista ?